Dechra Pharmaceuticals PLC (DPH) is a leading drug manufacturers-general business based in the UK. It opened the day at 3272p after a previous close of 3266p. During the day the price has varied from a low of 3256p to a high of 3330p. The latest price was 3270p (25 minute delay). Dechra Pharmaceuticals is listed on the London Stock Exchange (LSE) and employs 1,889 staff. All prices are listed in pence sterling.
Since the stock market crash in March caused by coronavirus, Dechra Pharmaceuticals's share price has had significant positive movement.
Its last market close was 3474p, which is 19.40% up on its pre-crash value of 2800p and 71.13% up on the lowest point reached during the March crash when the shares fell as low as 2030p.
If you had bought £1,000 worth of Dechra Pharmaceuticals shares at the start of February 2020, those shares would have been worth £855.36 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth £1,238.13.
|52-week range||2016.3682p - 3596p|
|50-day moving average||3315.5293p|
|200-day moving average||3177.3098p|
|Wall St. target price||2680.86p|
|Dividend yield||0.34p (1%)|
|Earnings per share (TTM)||32.8p|
All investing should be regarded as longer term. The value of your investments can go up and down, and you may get back less than you invest. Past performance is no guarantee of future results. If you’re not sure which investments are right for you, please seek out a financial adviser. Capital at risk.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
|1 week (2021-01-11)||-8.51%|
|1 month (2020-12-18)||3270|
|3 months (2020-10-16)||-5.98%|
|6 months (2020-07-17)||9.15%|
|1 year (2020-01-17)||15.38%|
|2 years (2019-01-18)||35.35%|
|3 years (2018-01-18)||62.04%|
|5 years (2016-01-18)||230.97%|
Valuing Dechra Pharmaceuticals stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Dechra Pharmaceuticals's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Dechra Pharmaceuticals's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 104x. In other words, Dechra Pharmaceuticals shares trade at around 104x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the FTSE 250 at the end of September 2019 (19.71). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
Dechra Pharmaceuticals's EBITDA (earnings before interest, taxes, depreciation and amortisation) is £84.5 million.
The EBITDA is a measure of a Dechra Pharmaceuticals's overall financial performance and is widely used to measure a its profitability.
|Revenue TTM||£515.1 million|
|Operating margin TTM||11.4%|
|Gross profit TTM||£291.6 million|
|Return on assets TTM||3.22%|
|Return on equity TTM||5.91%|
|Market capitalisation||£3.7 billion|
TTM: trailing 12 months
Dividend payout ratio: 10390.91% of net profits
Recently Dechra Pharmaceuticals has paid out, on average, around 10390.91% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 1% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), Dechra Pharmaceuticals shareholders could enjoy a 1% return on their shares, in the form of dividend payments. In Dechra Pharmaceuticals's case, that would currently equate to about 0.34p per share.
Dechra Pharmaceuticals's payout ratio would broadly be considered high, and as such this stock could appeal to those looking to generate an income. Bear in mind however that companies should normally also look to re-invest a decent amount of net profits to ensure future growth.
The latest dividend was paid out to all shareholders who bought their shares by 5 November 2020 (the "ex-dividend date").
Over the last 12 months, Dechra Pharmaceuticals's shares have ranged in value from as little as 2016.3682p up to 3596p. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (LSE average) beta is 1, while Dechra Pharmaceuticals's is 0.4899. This would suggest that Dechra Pharmaceuticals's shares are less volatile than average (for this exchange).
Dechra Pharmaceuticals PLC develops, manufactures, regulates, markets, and sells veterinary pharmaceuticals and related products for veterinarians worldwide. It operates through three segments: European Pharmaceuticals, North American Pharmaceuticals, and Pharmaceuticals Research and Development. The company offers various endocrinology, dermatology, analgesia and anesthesia, cardiovascular, and critical care products for dogs and cats; water soluble antibiotics, poultry vaccines, and pain management for poultry, pigs, and cattle; and lameness and pain management products for horses and ponies. It also provides pet nutrition products for supporting cats and dogs with various therapeutic conditions, such as allergies, obesity, heart, and kidney diseases. In addition, the company distributes veterinary pharmaceuticals and equipment; offers financial services; markets pet diets; and develops, regulates, manufactures, and markets crop protection. It markets its products through wholesaler and distributor networks. Dechra Pharmaceuticals PLC was incorporated in 1997 and is headquartered in Northwich, the United Kingdom.
Learn more about Transportation and Logistics Systems’ recent performance and where you can invest in Transportation and Logistics Systems shares. We also run through some helpful rules of thumb for any investor.
Learn more about Charlie’s Holdings’ recent performance and where you can invest in Charlie’s Holdings shares. We also run through some helpful rules of thumb for any investor.
Learn more about Lemonade’s recent performance and where you can invest in Lemonade shares. We also run through some helpful rules of thumb for any investor.
Learn more about Unity Software’s recent performance and where you can invest in Unity Software shares. We also run through some helpful rules of thumb for any investor
Learn more about FuelCell Energy’s recent performance and where you can invest in FuelCell Energy shares. We also run through some helpful rules of thumb for any investor.
Learn more about CloudCommerce’s recent performance and where you can invest in CloudCommerce shares. We also run through some helpful rules of thumb for any investor
Ever wondered how to buy shares in Zomedica Pharmaceuticals? We explain how and compare a range of providers that can give you access to many brands, including Zomedica Pharmaceuticals.
Ever wondered how to buy shares in YRC Worldwide? We explain how and compare a range of providers that can give you access to many brands, including YRC Worldwide.
Ever wondered how to buy shares in Xeros Technology Group? We explain how and compare a range of providers that can give you access to many brands, including Xeros Technology Group.
Ever wondered how to buy shares in Xpediator? We explain how and compare a range of providers that can give you access to many brands, including Xpediator.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.